Acelrx pharmaceuticals provides update on reduced fda rems requirements related to dsuvia®

Hayward, calif., may 19, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), ("acelrx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported that the u.s. food and drug administration (fda) has recently modified the dsuvia risk evaluation and mitigation strategies (rems) requirements with respect to healthcare setting audits.
ACRX Ratings Summary
ACRX Quant Ranking